Dexamethasone-(C₂₁-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

References

• HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935
   PubMed Web of Science ®Google Scholar
• XuJWLiQQTaoLLInvolvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cellsInt J Oncol20113961501150921805028
   PubMed Web of Science ®Google Scholar
• HurrellTOuthoffKThe in-vitro influences of epidermal growth factor and heregulin-â1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinomaCancer Cell Int20131319724119761
   PubMedGoogle Scholar
• LiuKChenHYouQShiHWangZThe siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cellMol Cell Biochem20143861–211712424158524
   PubMed Web of Science ®Google Scholar
• MoerkensMZhangYWesterLEpidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationBMC Cancer20141428324758408
   PubMed Web of Science ®Google Scholar
• SchneiderJRubioMPBarbazánMJRodriguez-EscuderoFJSeizingerBRCastresanaJSP-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumorsJ Natl Cancer Inst199486118508567910219
   PubMedGoogle Scholar
• LuYJingyanGBaorongSPengJXuYCaiSExpression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancerCancer Biomark201211521922623220854
   PubMed Web of Science ®Google Scholar
• CarlssonJShenLXiangJXuJWeiQTendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumorsOncol Lett20135120821423255921
   PubMed Web of Science ®Google Scholar
• LehneGGrasmo-WendlerUHBernerJMUpregulation of stem cell genes in multidrug resistant K562 leukemia cellsLeuk Res200933101379138519394083
   PubMed Web of Science ®Google Scholar
• MunozJLRodriguez-CruzVGrecoSJNagulaVScottoKWRameshwarPTemozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cellsMol Cancer Ther201413102399241125053824
   PubMed Web of Science ®Google Scholar
• SalomonDSBrandtRCiardielloFEpidermal growth factor-related peptides and their receptors in human malignanciesCrit Rev Oncol Hematol19951931832327612182
   PubMed Web of Science ®Google Scholar
• YaktapourNÜbelhartRSchülerJInsulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemiaBlood201312291621163323863897
   PubMed Web of Science ®Google Scholar
• LiZHZhangQZhangQPreclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by ofatumumab conjugated with auristatinInvest New Drugs2014321758623903896
   PubMed Web of Science ®Google Scholar
• LapalombellaRYuBTriantafillouGLenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsBlood2008112135180518918772452
   PubMed Web of Science ®Google Scholar
• StanglmaierMReisSHallekMRituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cellsAnn Hematol2004831063464515309525
   PubMed Web of Science ®Google Scholar
• WeitzmanJBetancurMBoisselLRabinowitzAPKleinAKlingemannHVariable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemiaLeuk Lymphoma20095081361136819562616
   PubMed Web of Science ®Google Scholar
• LvMLinZQiaoCNovel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activityCancer Lett20102941667320202740
   PubMed Web of Science ®Google Scholar
• AsgeirsdóttirSAKokRJEvertsMMeijerDKMolemaGDelivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugateBiochem Pharmacol200365101729173912754109
   PubMed Web of Science ®Google Scholar
• LimSHVaughanATAshton-KeyMFc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacyBlood201111892530254021768293
   PubMed Web of Science ®Google Scholar
• BeumPVPeekEMLindorferMALoss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cellsJ Immunol201118763438344721841127
   PubMed Web of Science ®Google Scholar
• RabinovichGAGabrilovichDSotomayorEMImmunosuppressive strategies that are mediated by tumor cellsAnnu Rev Immunol20072526729617134371
   PubMed Web of Science ®Google Scholar
• MaoYPoschkeIKiesslingRTumor-induced immune suppression: role of inflammatory mediators released by myelomonocytic cellsJ Intern Med2014276215417024597954
   PubMed Web of Science ®Google Scholar
• MelgertBNOlingaPJackVKMolemaGMeijerDKPoelstraKDexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cellsJ Hepatol200032460361110782909
   PubMed Web of Science ®Google Scholar
• BasuAShrivastavTGMaitraSKA direct antigen heterologous enzyme immunoassay for measuring progesterone in serum without using displacerSteroids200671322223016359715
   PubMed Web of Science ®Google Scholar
• De GoeijAFvan ZeelandJKBeekCJBosmanFTSteroid-bovine serum albumin conjugates: molecular characterization and their interaction with androgen and estrogen receptorsJ Steroid Biochem1986245101710313724140
   PubMedGoogle Scholar
• HeXKYuanZXWuXJXuCQLiWYLow molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studiesTheranostics20122111054106323227122
   PubMed Web of Science ®Google Scholar
• FunkDSchrenkHHFreiEDevelopment of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linkerJ Drug Target201119643444520677913
   PubMed Web of Science ®Google Scholar
• InapagollaRGuruBRKurtogluYEIn-vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammationInt J Pharm20103991–214014720667503
   PubMedGoogle Scholar
• OnishiHMatsuyamaMConjugate between chondroitin sulfate and prednisolone with a glycine linker: preparation and in vitro conversion analysisChem Pharm Bull201361990291223995354
   PubMed Web of Science ®Google Scholar
• GranfeldtAHvasCLGraversenJHTargeting dexamethasone to macrophages in a porcine endotoxemic modelCrit Care Med20134111e309e31823928834
   PubMed Web of Science ®Google Scholar
• EvertsMKokRJAsgeirsdóttirSASelective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugateJ Immunol2002168288388911777986
   PubMed Web of Science ®Google Scholar
• StanACRaduDLCasaresSBonaCABrumeanuTDAntineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigenCancer Res19995911151219892195
   PubMed Web of Science ®Google Scholar
• PimmMVPaulMAOgumuyiwaTBiodistribution and tumour localization of a daunomycin-monoclonal antibody conjugate in nude mice and human tumour xenograftsCancer Immunol Immunother19882732672713180150
   PubMed Web of Science ®Google Scholar
• WeaverDJVossEWAnalysis of rates of receptor-mediated endocytosis and exocytosis of a fluorescent hapten-protein conjugate in murine macrophage: implications for antigen processingBiol Cell19989021691819691434
   PubMed Web of Science ®Google Scholar
• Alfonso-PérezMLópez-GiralSQuintanaNELoscertalesJMartín-JiménezPMuñozCAnti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemiaJ Leukoc Biol20067961157116516603585
   PubMed Web of Science ®Google Scholar
• BürkleANiedermeierMSchmitt-GräffAWierdaWGKeatingMJBurgerJAOverexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemiaBlood200711093316332517652619
   PubMed Web of Science ®Google Scholar
• SöderbergAHossainARosénAA protein disulfide isomerase/thioredoxin-1 complex is physically attached to exofacial membrane tumor necrosis factor receptors: overexpression in chronic lymphocytic leukemia cellsAntioxid Redox Signal201318436337522775451
   PubMed Web of Science ®Google Scholar
• AwanFTLapalombellaRTrottaRCD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyBlood201011561204121319965644
   PubMed Web of Science ®Google Scholar
• StephensDMByrdJCImproving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapyHematol Oncol Clin North Am201327230332723561475
   PubMed Web of Science ®Google Scholar
• KlabusayMSukovaVCoupekPBrychtovaYMayerJDifferent levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseasesCytometry B Clin Cytom200772536337017428002
   PubMedGoogle Scholar
• CoyneCPNarayananLFludarabine-(C2-methylhydroxy-phosphoramide)-[anti-IGF-1R]: synthesis and selectively “targeted” anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549)J Pharm Drug Deliv Res20154112926613088
   PubMedGoogle Scholar
• GolfSWGraefVSchillerJTHischerHFunkWThin-layer chromatography – the forgotten alternative for the quantitative determination of steroidsBiomed Chromatogr1987251891923507234
   PubMedGoogle Scholar
• PawBMisztalGDzwonnikKThin-layer chromatographic analysis of fludarabine and formycin A in human plasmaActa Pol Pharm200057534134311126023
   PubMedGoogle Scholar
• PatelHA validated stability-indicating HPTLC method for the estimation of gemcitabine HCl in its dosage formJ Planar Chromatogr2012257780
   Web of Science ®Google Scholar
• BerridgeMVHerstPMTanASTetrazolium dyes as tools in cell biology: new insights into their cellular reductionBiotechnol Annu Rev20051112715216216776
   PubMedGoogle Scholar
• BerridgeMVTanASCharacterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reductionArch Biochem Biophys199330324744828390225
   PubMed Web of Science ®Google Scholar
• WatsonEDeaPChanKKKinetics of phosphoramide mustard hydrolysis in aqueous solutionJ Pharm Sci19857412128312924087195
   PubMed Web of Science ®Google Scholar
• SurabhiPSynthesis and Evaluation of Phosphoramide Mustard Prodrugs for Site-Specific Activation [Master Dissertation]Rutgers University Medicinal Chemistry Graduate ProgramNew Brunswick, NJ2007
   Google Scholar
• CoyneCPRossMBaileyJDual potency anti-HER2/neu and anti-EGFR anthracycline-immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin-A and verapamil P-glycoprotein inhibitionJ Drug Target200917647448919480561
   PubMed Web of Science ®Google Scholar
• CoyneCPJonesTPharrTSynthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinomaBioorg Med Chem2011191677621169024
   PubMed Web of Science ®Google Scholar
• CoyneCPJonesTSygulaABaileyJPinchukLEpirubicin-[anti-HER2/neu] synthesized with an epirubicin-(C13-imino)-EMCS analog: anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma in combination with organic seleniumJ Cancer Ther201121223926229727
   PubMedGoogle Scholar
• CoyneCPJonesTBearRSynthesis of epirubicin-(C3-amide)-[anti-HER2/neu] utilizing a UV-photoactivated epirubicinCancer Biother Radiopharm2012271415522191802
   PubMed Web of Science ®Google Scholar
• CoyneCPJonesTBearRSynthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate: cytotoxic anti-Neoplastic activity against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3J Cancer Ther201235A68971126225216
   PubMedGoogle Scholar
• BeyerURothen-RutishauserBUngerCDifference in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal-formulated doxorubicin as shown by confocal microscopyPharmacol Res20011812938
   Google Scholar
• Di StefanoGLanzaMKratzFMerinaLFiumeLA novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization. and preliminary biological properties of the conjugateEur J Pharm Sci2004234–539339715567293
   PubMed Web of Science ®Google Scholar
• SinkuleJARosenSTRadosevichJAMonoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in-vitro anti-tumor efficacy of different conjugation methodsTumour Biol19911241982061651554
   PubMedGoogle Scholar
• KanekoTWillnerDKnipeJONew hydrazone derivatives of adriamycin and their immunoconjugates: a correlation between acid-stability and cytotoxicityBioconjug Chem1991231331411932212
   PubMed Web of Science ®Google Scholar
• KratzFWarneckeAScheuermannKProbing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compoundJ Med Chem200245255523553312459020
   PubMed Web of Science ®Google Scholar
• UngerCHäringBMedingerMPhase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClin Cancer Res200713164858486617699865
   PubMed Web of Science ®Google Scholar
• MazuelCGroveJGerinGKeenanKPHPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasmaJ Pharm Biomed Anal20033351093110214656600
   PubMed Web of Science ®Google Scholar
• GreenfieldRSKanekoTDauesAEvaluation in-vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linkerCancer Res19905020660066072208122
   PubMed Web of Science ®Google Scholar
• LauABerubeGFordCHJNovel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in-vivoBioorg Med Chem1995310130513128564396
   PubMed Web of Science ®Google Scholar
• KrugerMBeyerUSchumacherPSynthesis and stability of four maleimide derivatives of the anti-cancer drug doxorubicin for the preparation of chemoimmunoconjugatesChem Pharm Bull1997452399401
   Web of Science ®Google Scholar
• FurgesonDYDreherMRChilkotiAStructural optimization of a “smart” doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumorsJ Control Release2006110236236916303202
   PubMed Web of Science ®Google Scholar
• LiangJFYangVCSynthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activityBioorg Med Chem Lett200515225071507516168650
   PubMed Web of Science ®Google Scholar
• SirovaMStrohalmJSubrVTreatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumor immunity in miceCancer Immunol Immunother2007561354716636810
   PubMed Web of Science ®Google Scholar
• WongBKDefeo-JonesDJonesREPSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metaboliteDrug Metab Dispos200129331331811181501
   PubMed Web of Science ®Google Scholar
• BidwellGL3rdDavisANFoktIPriebeWRaucherDA thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistanceInvest New Drugs200725431332617483874
   PubMed Web of Science ®Google Scholar
• AjajKAGraeserRFichtnerIIn-vitro and in-vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin BCancer Chemother Pharmacol200964241341819229536
   PubMed Web of Science ®Google Scholar
• RyppaCMann-SteinbergHFichtnerIIn-vitro and in-vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin aVb3Bioconjug Chem20081971414142218578486
   PubMed Web of Science ®Google Scholar
• HuangYFShangguanDLiuHMolecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cellsChem Bio Chem2009105862868
   Google Scholar
• RenYWeiDZhanXInhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an anti-sense oligodeoxynucleotide-doxorubicin conjugate in vitroBiotechnol Appl Biochem200541pt 213714315202936
   PubMedGoogle Scholar
• RenYZhanXWeiDLiuJIn-vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugateBiomed Pharmacother200458952052615511610
   PubMed Web of Science ®Google Scholar
• KovarLEtrychTKabesovaMDoxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cellsTumour Biol201031423324220556593
   PubMedGoogle Scholar
• LammersTSubrVUlbrichKSimultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriersBiomaterials200930203466347519304320
   PubMed Web of Science ®Google Scholar
• KrakovicovaHEthchTUlbrichKHPMA-based polymerconjugates with drug combinationsEur J Pharmacol2009373–440504412
   Google Scholar
• CaoNFengSSDoxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in-vitro and in-vivo evaluationBiomaterials200829283856386518606445
   PubMed Web of Science ®Google Scholar
• RodriguesPCBeyerUSchumacherPAcid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distributionBioorg Med Chem19997112517252410632061
   PubMed Web of Science ®Google Scholar
• KratzFAlbumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticlesJ Control Release2008132317118318582981
   PubMed Web of Science ®Google Scholar
• DillmanROJohnsonDEOgdenJBeidlerDSignificance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugatesMol Biotherapy198915250255
   PubMedGoogle Scholar
• EliasDJKlineLERobbinsBAMonoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinomaAm J Respir Crit Care Med19941504111411227921445
   PubMed Web of Science ®Google Scholar
• LelievreEGuillaudeuxJCardonaHHuman pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassayCancer Res19935315353635408339259
   PubMed Web of Science ®Google Scholar
• StarlingJJMaciakRSLawKLIn-vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexesCancer Res19915111296529722032233
   PubMed Web of Science ®Google Scholar
• JohnsonDAZimmermannJLLaguzzaBCIn-vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugatesCancer Immunol Immunother19882732412453180148
   PubMed Web of Science ®Google Scholar
• VoznesenskiiAIGalanovaYuVArchakovAICovalent binding of bleomycin to concanavalin A and immunoglobulin G enhances the ability of the bleomycin-Fe(II) complex to destroy the erythrocyte membraneBiomed Sci1991221471501723008
   PubMedGoogle Scholar
• ManabeYTsubotaTHarutaYProduction of a monoclonal antibody-bleomycin conjugate utilizing dextran T-40 and the antigen-targeting cytotoxicity of the conjugateBiochem Biophys Res Commun19831153100910146194796
   PubMed Web of Science ®Google Scholar
• BeyerURothTSchumacherPSynthesis and in-vitro efficacy of transferring conjugates of the anticancer drug chlorambucilJ Med Chem19984115270127089667961
   PubMed Web of Science ®Google Scholar
• KratzFBeyerURothTAlbumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in-vitro efficacyArch Pharm (Weinheim)1998331247539525088
   PubMed Web of Science ®Google Scholar
• YangDJLiuCWYuDFBisaminoethanethiol-targeting ligand conjugates and compositionsUS Patent US8236279 B2872012
   Google Scholar
• BonnyCCoquozDChenJConjugates with enhanced cell uptake activityU S Patent WO2006050930 A25182006
   Google Scholar
• JaimeJPagéMPaclitaxel immunoconjugate for the specific treatment of ovarian cancer in-vitroAnticancer Res2001212A1119112811396150
   PubMed Web of Science ®Google Scholar
• SafavyARaischKPSynthesis and biological evaluation of a paclitaxel immunoconjugateMethods Mol Med200510937538815585932
   PubMedGoogle Scholar
• JaimeJPagéMPaclitaxel antibody conjugates and trehalose for preserving the immunological activity after freeze-dryingCurr Med Chem200411443944614965225
   PubMed Web of Science ®Google Scholar
• DiJosephJFDougherMMEvansDYZhouBBDamleNKPreclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOPCancer Chemother Pharmacol201167474174920521053
   PubMed Web of Science ®Google Scholar
• TanakaMKanoYAkutsuMThe cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional anti-leukemic agents by isobologram analysis in-vitroAnticancer Res200929114589459620032408
   PubMed Web of Science ®Google Scholar
• DornanDBennettFChenYTherapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaBlood2009114132721272919633198
   PubMed Web of Science ®Google Scholar
• PollackVAAlvarezETseKFTreatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMBCancer Chemother Pharmacol200760342343517541593
   PubMed Web of Science ®Google Scholar
• OkeleyNMMiyamotoJBZhangXIntracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugateClin Cancer Res201016388889720086002
   PubMed Web of Science ®Google Scholar
• ChengVCHoPLYuenKYTwo probable cases of serious drug interaction between clarithromycin and colchicineSouth Med J200598881181316144178
   PubMed Web of Science ®Google Scholar
• BergerASChengCKPearsonPAIntravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathyInvest Ophthalmol Vis Sci19963711231823258843916
   PubMed Web of Science ®Google Scholar
• ShrivastavTGChaubeSKKariyaKPPrasadPKKumarDInfluence of different length spacers containing enzyme conjugate on functional parameters of progesterone ELISAJ Immunoassay Immunochem20133419410823323985
   PubMed Web of Science ®Google Scholar
• OgiharaTMiyalKNishiKIshibashiKKumaharaYEnzyme-labelled immunoassay for plasma cortisolJ Clin Endocrinol Metab19774419195319104
   PubMed Web of Science ®Google Scholar
• NakaoTTamamuraFTsunodaNKawataKDouble antibody enzyme immunoassay of cortisol in bovine plasmaSteroids19813811111206270851
   PubMed Web of Science ®Google Scholar
• NakaoTPractical procedure for enzyme immunoassay of progesterone in bovine serumActa Endocrinol19809322232276769271
   PubMedGoogle Scholar
• ErlangerBEBorekFBeiserSMSteroid-protein conjugates. II. Preparation and characterization of conjugates of bovine serum albumin with progesterone, deoxycorticosterone, and estroneJ Biol Chem195923451090109413654325
   PubMed Web of Science ®Google Scholar
• ErlangerBEBorekFBeiserSMLiebermanSSteroid-protein conjugates. I. Preparation and characterization of conjugates of bovine serum albumin with testosterone and with cortisoneJ Biol Chem1957228271372713475354
   PubMed Web of Science ®Google Scholar
• AliSMKhanARAhmadMUChenPSheikhSAhmadISynthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002)Bioorg Med Chem Lett200515102571257415863318
   PubMed Web of Science ®Google Scholar
• ChenPChienPYKhanARIn-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugateAnticancer Drugs2006171536116317290
   PubMed Web of Science ®Google Scholar
• ChiuMLTsengTTCMonbouquetteHGA convenient homogeneous enzyme immunoassay for estradiol detectionBiotechnol Appl Biochem2011581758221446962
   PubMed Web of Science ®Google Scholar
• HatzidakisGStefanakisAKrambovitisEComparison of different antibody-conjugate derivatives for the development of a sensitive and specific progesterone assayJ Reprod Fertil19939725575618501727
   PubMedGoogle Scholar
• KhatunSNaraSTripathiVDevelopment of ELISA for measurement of progesterone employing 17-alpha-OH-P-HRP as enzyme labelJ Immunoassay Immunochem200930218619619330644
   PubMed Web of Science ®Google Scholar
• BuckiRLeszczynskaKByfieldFJCombined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugateAntimicrob Agents Chemother20105462525253320308375
   PubMed Web of Science ®Google Scholar
• KobayashiNKatoYOyamaHAnti-estradiol-17beta single-chain Fv fragments: generation, characterization, gene randomization, and optimized phage displaySteroids200873141485149918824188
   PubMed Web of Science ®Google Scholar
• PangYNZhangYZhangZRSynthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targetingWorld J Gastroenterol20028591391712378641
   PubMed Web of Science ®Google Scholar
• QuanLDPurduePELiuXMDevelopment of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacyArthritis Res Ther2010125R17020836843
   PubMed Web of Science ®Google Scholar
• YamashitaKTakahashiMTsukamotoSNumazawaMOkuyamaMHonmaSUse of novel picolinoyl derivatization for simultaneous quantification of six corticosteroids by liquid chromatography-electrospray ionization tandem mass spectrometryJ Chromatogr A2007117312012817964584
   PubMed Web of Science ®Google Scholar
• KiewLVCheongSKSidikKChungLYImproved plasma stability and sustained release profile of gemcitabine via polypeptide conjugationInt J Pharm20103911–221222020214970
   PubMedGoogle Scholar
• AlexanderRLGreeneBTTortiSVKuceraGLA novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanismsCancer Chemother Pharmacol2005561152115789226
   PubMed Web of Science ®Google Scholar
• AlexanderRLMorris-NatschkeSLIshaqKSSynthesis of cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phophatidic acid conjugates with gemcitabine and cytosine arabinosideJ Med Chem200346194205420812954073
   PubMed Web of Science ®Google Scholar
• AlexanderRLKuceraGLLipid nucleoside conjugates for the treatment of cancerCurr Pharm Des20051191079108915853657
   PubMed Web of Science ®Google Scholar
• GuoPMaJLiSGuoZAdamsALGalloJMTargeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft modelCancer Chemother Pharmacol200148216917611561783
   PubMed Web of Science ®Google Scholar
• GuoZGalloJMSelective protection of 2′,2′-difluorodexoycytidine (gemcitabine)J Org Chem199964228319832211674754
   PubMed Web of Science ®Google Scholar
• CastelliFSarpietroMGCerutiMRoccoFCattelLCharacterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetryMol Pharm20063673774417140261
   PubMed Web of Science ®Google Scholar
• LagisettyPVilekarPAwasthiVSynthesis of radiolabeled cytarabine conjugatesBioorganic Med Chem Lett2009191647644767
   PubMed Web of Science ®Google Scholar
• RatcliffeKEFraserHMSellarRRivierJMillarRPBifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of actionEndocrinology2006147157157916223868
   PubMed Web of Science ®Google Scholar
• CernýIPouzarVHillMHavlíkováHHamplRSyntheses of 19-[O-(carboxymethyl)oxime] haptens of epipregnanolone and pregnanoloneSteroids200671212012816242742
   PubMed Web of Science ®Google Scholar
• JonesCDMasonNRThe use of 6alpha-and 6beta-carboxymethyl testosterone-bovine serum albumin conjugates in radioimmunoassay for testosteroneSteroids197525123321167430
   PubMed Web of Science ®Google Scholar
• NambaraTOhkuboTShimadaKAntigenic properties of estriol 3-glucuronide-[C-6]-bovine serum albumin conjugates having oxime bridgesJ Pharmacobiodyn1983696926976655549
   PubMedGoogle Scholar
• ShihLBGoldenbergDMXuanHLuHWMattesMJHallTCInternalization of an intact doxorubicin immunoconjugateCancer Immunol Immunother199438292988306371
   PubMed Web of Science ®Google Scholar
• SliwkowskiMXLofgrenJALewisGDHotalingTEFendlyBMFoxJANonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)Semin Oncol1999264 suppl 12607010482195
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• GongCYaoYWangYUp-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancerJ Biol Chem201128621191271913721471222
   PubMed Web of Science ®Google Scholar
• ScaltritiMEichhornPJCortésJCyclin E amplification/over-expression is a mechanism of trastuzumab resistance in HER2+ breast cancer patientsProc Natl Acad Sci U S A201110893761376621321214
   PubMed Web of Science ®Google Scholar
• PandyaKMeekeKClementzATargeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrenceBr J Cancer2011105679680621847123
   PubMed Web of Science ®Google Scholar
• MorgilloFKimWKimEImplications of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res20071392795280317473213
   PubMed Web of Science ®Google Scholar
• MorgilloFWooJKKimESHeterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of surviving expression counteract the anti-tumor action of ErlotinibCancer Res20066620101001011117047074
   PubMed Web of Science ®Google Scholar
• Sartore-BianchiADi NicolantonioFNichelattiMMulti-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerPLoS One2009410e728719806185
   PubMed Web of Science ®Google Scholar
• WeickhardtATebbuttNMariadasonJStrategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathwayCurr Cancer Drug Targets201010882483320718704
   PubMed Web of Science ®Google Scholar
• ModjtahediHEssapenSEpidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunitiesAnticancer Drugs2009201085185519826350
   PubMed Web of Science ®Google Scholar
• DempkeWHeinemannVRas mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinomaAnticancer Res201030114673467721115922
   PubMed Web of Science ®Google Scholar
• SchmitzSKaminsky-ForrettMCHenrySPhase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)Ann Oncol20122382153216122234739
   PubMed Web of Science ®Google Scholar
• ChiKNGleaveMEFazliLA phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerClin Cancer Res201218123407341322553344
   PubMed Web of Science ®Google Scholar
• AtzoriFTaberneroJCervantesAA phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsClin Cancer Res201117196304631221810918
   PubMed Web of Science ®Google Scholar
• BitelmanCSarfsteinRSarigMIGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancerCancer Lett2013335115315923402816
   PubMed Web of Science ®Google Scholar
• KlitgaardJLKoefoedKGeislerCCombination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cellsBr J Haematol2013163218219323927424
   PubMed Web of Science ®Google Scholar
• LefebvreMLKrauseSWSalcedoMEx-vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serumJ Immunother200629438839716799334
   PubMed Web of Science ®Google Scholar
• ManchesOLuiGChaperotLIn-vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood2003101394995412393572
   PubMed Web of Science ®Google Scholar
• StevensonFKBellAJCusackRPreliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibodyBlood1991775107110791995092
   PubMed Web of Science ®Google Scholar
• LiMXiaoXZhangWLiuLXiNWangYAFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cellsCell Immunol2014290223324425117605
   PubMed Web of Science ®Google Scholar
• ZhangLQianZCaiZSynergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivoAm J Hematol200984955355919565649
   PubMed Web of Science ®Google Scholar
• FeiFLimMGeorgeAACytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cellsLeukemia201529478879725134458
   PubMed Web of Science ®Google Scholar
• CaronPCLaiLTScheinbergDAInterleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemiaClin Cancer Res19951163709815888
   PubMed Web of Science ®Google Scholar
• PietrasRJPegramMDFinnRSManevalDASlamonDJRemission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene19981717223522499811454
   PubMed Web of Science ®Google Scholar
• MarchesRUhrJWEnhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cellsInt J Cancer2004112349250115382077
   PubMed Web of Science ®Google Scholar
• LinNUCareyLALiuMCPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200826121993199918421051
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• KuteTESavageLStehleJRBreast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killingCancer Immunol Immunother200958111887189619340424
   PubMed Web of Science ®Google Scholar
• NarayanMWilkenJAHarrisLNBaronATKimblerKDMaihleNJTrastuzumab-induced HER reprogramming in “resistant” breast carcinoma cellsCancer Res20096962191219419276389
   PubMed Web of Science ®Google Scholar
• ChenFLXiaWSpectorNLAcquired resistance to small molecule ErbB2 tyrosine kinase inhibitorsClin Cancer Res200814216730673418980964
   PubMed Web of Science ®Google Scholar
• RitterCAPerez-TorresMRinehartCHuman breast cancer cells selected for resistance to trastuzumab in-vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkClin Cancer Res200713164909491917699871
   PubMed Web of Science ®Google Scholar
• NandaRTargeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directionsRev Recent Clin Trials20072211111618473995
   PubMedGoogle Scholar
• MitraDBrumlikMJOkamgbaSUAn oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistanceMol Cancer Ther2009882152216219671734
   PubMed Web of Science ®Google Scholar
• KöninkiKBarokMTannerMMultiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsCancer Lett2010294221121920193978
   PubMed Web of Science ®Google Scholar
• Oliveras-FerrarosCVazquez-MartinACufíSInhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapiesBiochem Biophys Res Commun2011407241241921402055
   PubMed Web of Science ®Google Scholar
• BarokMTannerMKöninkiKTrastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in-vivoBreast Cancer Res2011132R4621510863
   PubMed Web of Science ®Google Scholar
• Oliveras-FerrarosCVazquez-MartinAMartin-CastillóBPathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)Int J Oncol201037366967820664936
   PubMed Web of Science ®Google Scholar
• García-SáenzJAMartínMCallesABevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancerJ Chemother200820563263919028628
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JoneBShakSUse of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2N Engl J Med200134411786792
   Web of Science ®Google Scholar
• HarrisCAWardRLDobbinsTADrewAKPearsonSThe efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysisAnn Oncol20112261308131721119031
   PubMed Web of Science ®Google Scholar
• SivamGPMartinPJReisfeldRAMuellerBMTherapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanomaCancer Res19955511235223567757986
   PubMed Web of Science ®Google Scholar
• YangHMReisfeldRADoxorubicin conjugated with monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses growth of established tumor xenografts in nude miceProc Natl Acad Sci U S A1988854118911933422487
   PubMed Web of Science ®Google Scholar
• SapraPSteinRPickettJAnti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograph and in monkeysClin Cancer Res200511145257526416033844
   PubMed Web of Science ®Google Scholar
• NavabRChevetEAuthierFDi GuglielmoGMBergeronJJBrodtPInhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functionsJ Biol Chem200127617136441364911278993
   PubMed Web of Science ®Google Scholar
• HansenHJOngGLDirilHInternalization and catabolism of radiolabeled antibodies to the MHC class-II invariant chain by B-cell lymphomasBiochem J1996320pt 12933008947500
   PubMedGoogle Scholar
• WangFJiangXYangDCElliottRLHeadJFDoxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cellsAnticancer Res2000202A79980810810357
   PubMed Web of Science ®Google Scholar
• RéginaADemeuleMChéCAntitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2Br J Pharmacol2008155218519718574456
   PubMed Web of Science ®Google Scholar
• AsakuraTTakahashiNTakadaKInoueTOhkawaKDrug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cellsAnticancer Drugs1997821992039073316
   PubMed Web of Science ®Google Scholar
• MazelMClairPRousselleCDoxorubicin-peptide conjugates overcome multidrug resistanceAnticancer Drugs200112210711611261883
   PubMed Web of Science ®Google Scholar
• LamWLeungCHChanHLFongWFToxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran sizeAnticancer Drugs200011537738410912954
   PubMed Web of Science ®Google Scholar
• DubikovskayaEAThorneSHPillowTHContagCHWenderPAOvercoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transportersProc Natl Acad Sci U S A200810534121281213318713866
   PubMed Web of Science ®Google Scholar
• PegramMDLopezAKonecnyGSlamonDJTrastuzumab and chemotherapeutics: drug interactions and synergiesSemin Oncol2000276 suppl 112125 discussion 92–10011236023
   PubMed Web of Science ®Google Scholar
• SlamonDPegramMRationale for trastuzumab (Herceptin) in adjuvant breast cancer trialsSemin Oncol2001281 suppl 3131911301370
   PubMed Web of Science ®Google Scholar
• BooneJJBhosleJTilbyMJHartleyJAHochhauserDInvolvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agentsMol Cancer Ther20098113015302319887555
   PubMed Web of Science ®Google Scholar
• MedenHBenekeAHesseTNovophashennyIWischnewskyMWeekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot studyAnticancer Res2001212B1301130511396203
   PubMed Web of Science ®Google Scholar
• WinerEPBursteinHJNew combinations with Herceptin in metastatic breast cancerOncology200161suppl 2505711694788
   PubMedGoogle Scholar
• KimSPrichardCNYounesMNCetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude miceClin Cancer Res200612260060716428506
   PubMed Web of Science ®Google Scholar
• LandriscinaMMaddalenaFFabianoAPiscazziALa MacchiaOCignarelliMErlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cellsAnticancer Res201030247348020332457
   PubMed Web of Science ®Google Scholar
• CiardielloFBiancoRDamianoVAntitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225Clin Cancer Res19995490991610213228
   PubMed Web of Science ®Google Scholar
• QuekRWangQMorganJACombination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumorsClin Cancer Res201117487187921177764
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTPalassiniESunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor responseMol Cancer Ther2010951286129720457621
   PubMed Web of Science ®Google Scholar
• LynnKDUdugamasooriyaDGRolandCLCastrillonDHKodadekTJBrekkenRAGU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancerBMC Cancer20101039720673348
   PubMed Web of Science ®Google Scholar
• ZhangLYuDHicklinDJCombined anti-fetal liver kinase 1 monoclonal antibody (anti-VEGFR) and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosisCancer Res20026272034204211929822
   PubMed Web of Science ®Google Scholar
• EdelmannMNOggRJScogginsMADexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: a report from the SJLIFE cohortPediatr Blood Cancer201360111778178423775832
   PubMed Web of Science ®Google Scholar
• WarrisLTvan den Heuvel-EibrinkMMden HoedMAAarsenFKPietersRvan den AkkerELDoes dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic reviewPediatr Blood Cancer20146171313131824532490
   PubMed Web of Science ®Google Scholar
• WaberDPMcCabeMSebreeMNeuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01Pediatr Blood Cancer201360111785179123832430
   PubMed Web of Science ®Google Scholar
• KanatOOzetAAtaerginSModified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphomaMed Princ Pract201019534434720639655
   PubMed Web of Science ®Google Scholar
• LerzaRBottaMBarsottiBDexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphomaLeuk Lymphoma20024351129113212148896
   PubMed Web of Science ®Google Scholar
• WatanabeNTakahashiTSugimotoNExcellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximabInt J Clin Oncol200510535736116247665
   PubMedGoogle Scholar
• WielckensKDelfsTMuthAFreeseVKleebergHJGlucocorticoid-induced lymphoma cell death: the good and the evilJ Steroid Biochem1987271–34134193121924
   PubMedGoogle Scholar
• MaoYTriantafillouGHertleinEMilatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesClin Cancer Res201319234735623209030
   PubMed Web of Science ®Google Scholar
• PileckyteRJurgutisMValceckieneVDose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemiaLeuk Lymphoma20115261055106521599591
   PubMed Web of Science ®Google Scholar
• DomenechCSuciuSDe MoerlooseBDexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trialHaematologica20149971220122724727815
   PubMed Web of Science ®Google Scholar
• BelzKSchoenebergerHWehnerSSmac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assemblyBlood2014124224025024855207
   PubMed Web of Science ®Google Scholar
• FleuryIPrimeauMDoreauAPolymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemiaAm J Pharmacogenomics20044533134115462611
   PubMedGoogle Scholar